Everyday hospitals are closing down their diabetes education programs making it harder for our patients to get the knowledge to manage their diabetes. You may not know this but in 1997 when funding was made for education for patients, the recognized experts, CDE’s were not included in the bill!! Now …
Read More »Diabetes In Control
Flu Vaccine Has No Benefits for the Elderly?
A study published online in the journal Vaccine found the influenza vaccine had no impact on emergency admissions in the elderly.
Read More »Fish Oil Supplements Reduce Adiposity in Type 2 Diabetics
French researchers report in the American Journal of Clinical Nutrition for December that, two months of daily fish oil supplements reduces adiposity and atherogenic markers in women with type 2 diabetes.
Read More »Metformin Cost Effective in Preventing Diabetes
According to recent research published in the journal Diabetes Care, “In the Indian Diabetes Prevention Program (IDPP), a 3-year randomized, controlled trial, lifestyle modification (LSM) and metformin helped to prevent type 2 diabetes in subjects with impaired glucose tolerance (IGT).
Read More »Moderate Alcohol Consumption Lowers Fasting Glucose 20mg/dL
A daily glass of wine with dinner for those with type 2 diabetes lowers fasting plasma glucose (FPG), Israeli researchers report in the December issue of Diabetes Care.
Read More »New TZD With Antiatherogenic Effects Without Weight Gain
A new specific peroxisome proliferator-activated receptor (PPAR) modulator has demonstrated promise in a new study reported in November issue of Diabetes.
Read More »Takeda Submits New Drug Application For The Next DPP-IV Inhibitor Alogliptin
Takeda Pharmaceutical Company Limited announced today that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes.
Read More »New TZD’s Have Potent Antidiabetes and Antiatherogenic Effects
A new specific peroxisome proliferator-activated receptor (PPAR) modulator has demonstrated promise in a new French study, according to a report in the November issue of Diabetes. persons.
Read More »Statins Reduce All-Cause Mortality 22% in Elderly CHD Patients
In elderly patients with documented coronary heart disease (CHD), statins reduce all-cause mortality, as well as CHD mortality, nonfatal myocardial infarction, the need for revascularization, and stroke, a new review has shown. Investigators say that the magnitude of benefit, with statins reducing all-cause mortality 22%, is larger than previously estimated
Read More »Lack of Deep Sleep Raises Diabetes Risk
Three nights of interrupted slumber upsets young people’s blood sugar levels the same as if they gained 20-30 pounds,, study finds
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.